Harmane is a benzodiazepine receptor inhibitor (IC50=7 µM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and alpha2-adrenergic receptor of 24 µM, 2.8 µM, 0.5 µM, 5 µM, and 18 µM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF)[1][2][3][4][5][6].
